Cagrilintide
RENEW 2
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 330
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cagrilintide | Obesity + T2D | n/r | 64 | n/r | n/r |
| Placebo | Obesity + T2D | n/r | 64 | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Cagrilintide
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 330
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cagrilintide | Obesity + T2D | n/r | 64 | n/r | n/r |
| Placebo | Obesity + T2D | n/r | 64 | n/r | n/r |